Near Miss Data for Traffic Safety Brought to the Midwest to Help Save Lives
25. Juni 2024 11:12 ET
|
TAPCO Companies
Crash data isn't enough. Viva helps communities gain insight to interactions on their roadways to create safer travels for all.
Golden Predator Mining Corp. Announces Termination of Arrangement Agreement with Viva Gold Corp.
03. Mai 2021 07:30 ET
|
Golden Predator Mining Corp.
VANCOUVER, British Columbia, May 03, 2021 (GLOBE NEWSWIRE) -- Golden Predator Mining Corp. (TSX.V: GPY; OTCQX: NTGSF) ("Golden Predator") announces that the Company and Viva Gold Corp. (“Viva Gold”)...
Physeon Positive Clinical Trial Results for its Veinplicity® Device to be Published in The Journal of Vascular Access
01. April 2019 09:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14. Februar 2019 13:42 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Mayo Clinic to Conduct US “VIVA” Trial for Veinplicity
04. Februar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21. Januar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Bolsters Management Team with New Appointments
17. Dezember 2018 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced the...
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity
12. November 2018 09:00 ET
|
Physeon
Important Milestone for Veinplicity Study SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology...
Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity
29. Oktober 2018 08:00 ET
|
Physeon
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...